SEC Filing Summary: Access Pharmaceuticals, Inc. (10-Q)
Business Context and Reporting Period
Company: Access Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: An emerging biopharmaceutical company focused on nanopolymer chemistry and drug delivery technologies. The company has one FDA-cleared product (MuGard for oral mucositis) and several candidates in clinical or pre-clinical development, including ProLindac (cancer) and Thiarabine (cancer). The company operates with a significant accumulated deficit and relies on capital raises and licensing agreements for funding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2010 | Six Months Ended June 30, 2009 |
|---|---|---|
| Total Revenues | $207,000 | $104,000 |
| Net Income (Loss) | $2,879,000 | $(4,297,000) |
| Net Income Allocable to Common Stockholders | $1,991,000 | $(5,260,000) |
| EPS (Basic/Diluted) | $0.13 / $0.11 | $(0.48) / $(0.48) |
| Operating Expenses | $3,790,000 | $4,155,000 |
| Cash and Cash Equivalents (End of Period) | $2,758,000 | $1,231,000 |
| Working Capital Deficit | $(5,230,000) | $(7,949,000) |
| Long-Term Debt | $5,500,000 | $5,500,000 |
| Accumulated Deficit | $(239,816,000) | $(241,807,000) |
Material Changes vs. Prior Period
- Profitability Shift: The company reported a net income of $2.88 million for the six months ended June 30, 2010, compared to a net loss of $4.30 million in the same period in 2009. This reversal is primarily driven by a non-cash gain on change in fair value of derivative liability of $6.24 million and a $509,000 gain from negotiated payables/write-offs.
- Revenue Growth: Total revenues increased to $207,000 from $104,000, driven by licensing revenues ($174,000 vs. $104,000) and the initiation of royalty revenue ($33,000 vs. $0) from the MuGard product.
- Expense Reduction: Total operating expenses decreased by $365,000 to $3.79 million. General and administrative expenses dropped significantly ($603,000 decrease) due to reduced consulting fees, lower liquidated damages accruals, and terminated license fees, partially offset by higher investor relations and salary costs.
- Liquidity Improvement: Cash balances increased to $2.76 million from $607,000 at the end of 2009, largely due to a January 2010 equity offering that raised approximately $5.85 million net of costs.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Risk: Management states that capital resources are adequate to fund operations only into the first quarter of 2011. The company explicitly states it will be required to seek additional financing within the next twelve months. Failure to secure funding could jeopardize operations.
- Unusual Items: The reported net income is heavily influenced by non-operating, non-cash items, specifically the $6.24 million derivative gain and $509,000 gain on negotiated payables. Operating cash flow remains negative at $(3.83) million.
- Internal Control Weakness: The company disclosed a material weakness in internal controls over financial reporting, specifically regarding the lack of segregation of duties and insufficient accounting staff (all financial reporting is performed by the CFO). Disclosure controls were deemed ineffective.
- Debt and Dividends: The company has $5.5 million in convertible notes due in September 2011. Additionally, $3.55 million in preferred stock dividends are accrued and unpaid, with $857,000 in accrued liquidated damages related to registration statement delays.
- Product Outlook: MuGard is expected to launch in the U.S. in the third quarter of 2010. ProLindac is in Phase 2 trials for ovarian cancer.
Investor Verification Checklist
- Derivative Liability Valuation: Verify the assumptions and fair value calculations used to determine the $6.24 million gain on the derivative liability, as this is the primary driver of reported profitability.
- Cash Burn Rate: Confirm the sustainability of the $470,000 monthly net cash burn rate and the timeline for the next capital raise given the Q1 2011 runway.
- Debt Maturity: Assess the company's ability to refinance or repay the $5.5 million convertible note due in September 2011.
- Internal Controls: Review the progress on hiring accounting staff and implementing procedures to remediate the material weakness in financial reporting.
- Preferred Stock Obligations: Evaluate the impact of the $3.55 million accrued preferred dividends and $857,000 liquidated damages on future cash flow and equity dilution.